Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06260514 · ClinicalTrials.gov registry record · Phase 1
Study of APR-1051 in Patients With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by Aprea Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 3
- Study locations
NCT06260514: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Aprea Therapeutics.
NCT06260514 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Aprea Therapeutics. The registered enrollment target is 90 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (53% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06260514, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Aprea Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Primary Outcome
* Part 1 dose escalation: Incidence of adverse Events (AE), serious AEs (SAE), treatment-related AEs, AEs that would qualify as a dose-limiting toxicity (DLT), changes in clinical laboratory values, vital signs, ECG, ECHO * Part 1 dose escalation: Severity of adverse Events (AE), serious AEs (SAE), treatment-related AEs, and changes in clinical laboratory values, vital signs, ECG, ECHO according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0
Conditions Studied
Interventions
- DRUG APR-1051
Study Locations (3)
Texas
- MD Anderson Cancer Center (MDACC) - Houston
- NEXT Oncology -Dallas - Irving
- NEXT Oncology -San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2024-06-13 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What NCT06260514 shows while recruiting
NCT06260514 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which APR-1051 is the first listed.
NCT06260514 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06260514 about?
NCT06260514 is a clinical study titled "Study of APR-1051 in Patients With Advanced Solid Tumors". The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
What is the current status of trial NCT06260514?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2024-06-13. Estimated completion is 2028-06.
What conditions does trial NCT06260514 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06260514?
The interventions under investigation include: APR-1051 (DRUG).
Who is sponsoring clinical trial NCT06260514?
This trial is sponsored by Aprea Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06260514 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06260514's enrollment target sits among peer trials
90 123rd of 189 higher than 63 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI